Search

Pancreatic ductal adenocarcinoma (PDAC) is the most deadly common cancer, with fewer than ten per-cent of patients surviving five years from diagnosis. In contrast to many other cancers, the grim prognosis ofPDAC has remained largely the same over the past thirty years, reflecting our relatively poor understandingof the disease. This situation may soon change: recent large-scale efforts have produced detailed molecularand clinical data for almost a thousand cases of PDAC, finally enabling detailed dissection of the cancer’smolecular basis. This work used these new data to directly address two questions linked to PDAC’s excep-tionally poor prognosis: what are the biological processes that drive poor prognosis in PDAC? and can wedevelop a practical and effective prognostic staging system to better guide PDAC treatment?Chapter 2 considered the first question, using a gene expression factorisation approach to identify two meta-genes that determine survival in PDAC. These metagenes were linked to the biological processes of prolifera-tion, and the EMT, and were also prognostic in a number of other solid tumours, revealing these processes asgenerally important to cancer patient survival.Chapter 3 addressed the second question, developing a pilot tool to estimate the prognosis of a PDAC pa-tient, and guide the decision of whether to resect that patient’s tumour. The tool is unique in that it can beapplied prior to resection, and its validation performance was competitive with gold standard post-resectionmethods. This performance might be improved through better selection of prognostic biomarkers; this is thesubject of Chapter 4, which describes a method for the identification of biomarkers that are well-suited fordevelopment into clinical tests.PDAC has an exceptionally poor prognosis, but better understanding of the disease, and improvements in itsmanagement, can yield incrementally better outcomes. The work presented here focused on understandingand predicting prognosis